Diefreeandsell Posted - 3 days ago

@johnnybokc got approved for multiple sclerosis drug Briumvi in Dec 2022 and slowly taking mkt share from ocrevus $RHHBY and kesimpta $NVS .

Nosferatus Posted - 3 days ago

$MCRB $XBI $NVS $RHHBY $SPX please watch this video from minute 15. we will soon be bought at a minimum of USD 10 per share https://youtu.be/94NcNu12hDE?si=yAmH6VNYX6XFQ18E

Grande4587258 Posted - 3 days ago

$RHHBY Blast 💥 Off

LMDXWILLBOOM Posted - 4 days ago

$LMDX The structure of this deal is very collaborative sounding. What shareholders receive i cannot say for sure, but since FDA belongs to Lumiradx according to FDA themselves that can only mean I was correct in my assumption that Columbia holds the device they are marketing. It could also mean that we'll also receive shares of $RHHBY in a 9 or 10:1 ratio since Roche has a pending amount set aside & who knows with DNEDX. Patience friends it's coming.

DeepDown Posted - 4 days ago

$OMGA worth to buy some. $RHHBY and $NVO will pay up

LMDXWILLBOOM Posted - 1 week ago

$LMDX don't worry guys! I'm trolling both $rhhby & Lumira on linked in.

Thagger Posted - 1 week ago

@FalconTech Sub q seems is a non starter. Just PR from $RHHBY. A lot of things can happen during the infusion and I’m not sure sub q will be any less. When your heart rate goes up to 180+ what do you do? Your throat itches and you have hives and whatever else side effects who will give you Benadryl, solumerol, steroids etc when you’re already freaking out? Most people I would think would opt for infusion center.

InvestingBlue Posted - 1 week ago

$SPY starting a position in $FMC and $RHHBY both stocks are a great value currently.

GPS_OS_21_vs_SOC_5 Posted - 1 week ago

$SLS Targeted AML therapy is the way of the future. $kura's menin inhibitor Ziftomenib targeting kmt2a, is worth $1.6B . B. - Based on Top Line Phase 2 data published Jan 30th. - - SLS009 100% orr, in end stage dying ASXL1 + AML patients - $abbv $rhhby $bmy would pay $25 per sls share just for 009 Right Now. P2 Data in todays Clinical Environment w Genetic Markers is Like P3 Data was 10 years ago - back then p3's were needed to prove the drugs worked, Now We Know based on the BioMarkers. The Kicker - SLS 009 has had no Dose Limiting Toxicity, not one patient with a serious grade 3 or 4 Side Effect, not 1.

InvestingBlue Posted - 1 week ago

$RHHBY why does this perform so poorly? Company is a super value.

_rand0m Posted - 1 week ago

$TGTX $RHHBY look out, Briumvi is coming. $NVS look out, sub-cutaneous Briumvi is coming.

LilJimmy007 Posted - 1 week ago

$TGTX does $RHHBY CEO see it yet?

Okadarlan Posted - 1 week ago

$RHHBY Adding long here and hoping 27. shows support.

BTECHINV Posted - 1 week ago

As an off-and-on shareholder of $PFE and $RHHBY, would be particularly smart move for either one in my opinion. For Roche, since Carmot has GLP-1/GIP and GLP-1 mono in the works, PEMVIDUTIDE would add a powerful new MOA (GlucagonR agonism) with best in class characteristics to help develop a formidable GLP-1 portfolio AND get into the OBESITY market much faster as P3 is 2H 2024. For Pfizer, would be a major addition to a strong core medicine franchise and have the potential to be Lipitor 2.0 for this new GLP-1 era (in my opinion). Disclosure: Long Roche, not investment advice.

WhackaMole Posted - 04/29/24

$AXDX IMHO, If I were the head of Biomereiux, I would make a bid for this company to keep the technology away from competitors. At the very least, they would make it much more expensive for $BDX and $RHHBY. Their bankers should start making calls and pitch this to their strategic clients.

Broview Posted - 04/28/24

$RHHBY undervalued whole pharmaceutical sectors? Waiting for the best moment to bet?

Maverick11 Posted - 04/28/24

@Miha241 I think positive NASH data takes us to $100. $RHHBY or $PFE buyout takes us to $185+.

NEWBIGTECH Posted - 04/26/24

$AMGN $JNJ $PFE $RHHBY $ENSC

NEWBIGTECH Posted - 04/26/24

$ENSC is looking for a partner to help with Opioid Addiction. Has FDA Approval on for its PF614-MPAR® technology. SO Does it get $JNJ $AMGN $PFE or $RHHBY .. Get the word out, maybe competing Bids for this Technology. Who has the made an offer? Are they aware that $ENSC is the only Drug company with this technology?

Maverick11 Posted - 04/26/24

$VKTX This baby is definitely acting like $RHHBY is coming in Monday AM w/ announcement that we are its new wholly owned sub… go $VKTX…

groots Posted - 04/25/24

$LMDX $RHHBY $28.90 52 week low ALL UP FROM HERE ALL CAPS INVESTORS!

RainbowTrump Posted - 04/25/24

$RHHBY directly mentions $VKTX as the data leader. You have to imagine all the big pharma discussing this and keeping Viking on their radars

Okenrav Posted - 04/25/24

@mike_swiss_r @ILUVSPEWINGNONSENSE @BiotechAC YES SIR! These "limited experience" labs have been developing & producing CAR-Ts since the early 2000s. These "li,ited experience" labs, as you call them, are 100 years ahead of anything BP sells at the moment, but that's another discussion. Anyway, here's a reall question for you....If I am $PFE or $MRK or $RHHBY what's to stop me from making TILs? Why would I need to buy $IOVA 10x it's market cap when I can build a production line and approve the manufacturing process for 20x less?

LMDXWILLBOOM Posted - 04/25/24

$MULN This 🤡 hey $lmdx how many reverse splits did we have? 0....we have a $rhhby deal on table. Former CEO & partners founders of medisense & Alere not to mention Billy Gates & Richard Mashaal invested (same guy who ran $gme from 10 to 500.) What has David Michery accomplished? Running 7 businesses under. Dillution/RS/bankruptcy. Ok pal you got me!

jlemx Posted - 04/24/24

$RHHBY discontinued RG6286 trial in CRC. $AGEN on the contrary, Agenus continues to provide excellent data in CRC with Bot/Bal combo.

DonCorleone77 Posted - 04/24/24

$RHHBY Roche reports Q1 group sales CHF 14.4B vs. CHF 15.3B last year Group sales grew by 2% at constant exchange rates, driven by the strong growth of newer medicines and diagnostics. Excluding COVID-19-related products, sales increased by 7%. Going forward, there will be no further material impact of COVID-19 sales decline. Roche CEO Thomas Schinecker: "We had a strong start into the year, with both our divisions reporting high single digit growth in their base business - excluding COVID-19 sales. After this quarter, the COVID-19-related impact on sales is largely behind us. The appreciation of the Swiss franc versus most currencies impacted sales reported in Swiss francs compared to the same period last year. The uptake of our eye medicine Vabysmo continues its momentum. We are pleased about the US approval of Xolair as the first and only medicine for multiple food allergies. Further, we recently received the US approval for Alecensa in early-stage lung cancer. With an unprecedented 76% reduction in the risk of disease recurrence or death versus chemotherapy, Alecensa significantly improves upon the standard of care for this specific form of lung cancer. We are confident of growing our Group sales in the mid single digit range this year and therefore we confirm our outlook for 2024."

DonCorleone77 Posted - 04/24/24

$RHHBY Roche confirms outlook for 2024 Roche expects an increase in Group sales in the mid single digit range. Core earnings per share are targeted to develop broadly in line with sales growth, excluding the impact from the resolution of tax disputes in 2023. Roche expects to further increase its dividend in Swiss francs.

LMDXWILLBOOM Posted - 04/23/24

$LMDX coincidence that Lumiradx has their next event tomorrow, same day as $rhhby Q1? Maybe. Maybe this is where the good times are gonna roll? Who knows! But I'm hodling! Next gen diagnostics here.

Makena2017 Posted - 04/23/24

$IBRX IPO almost a decade ago at $46 with 0 revenue 0 approvals, what do ya think at $5.50 with a MAJOR oncology approval and pipeline $MRK $BMY $RHHBY $PFE would pay dearly for ?

GPS_OS_21_vs_SOC_5 Posted - 04/22/24

$SLS Unblinded, Binary, Fda Registrational Ph 3 results, worth Many Billions, Results 4 years in the making are now Imminent, coming in by 'late April'. - a positive P3 result, Gps Os better than 12.8 months w control at 8 or less and this $80M of manipulated equity is instantly worth some number of Billions. Gps immunotherapy will treat 25,000 aml remission patients. $6B TAM While, we are expecting the Gps results - likely this week, keep in mind, 009, now in 3, Phase 2 trials, has a direct market comp worth $1.4b, $KURA, also in P2, for an AML subset SLS009 top-line P2 100% CR rates in the RP2D for End Stage, dying AML patients relapsed, refractory to Aza Ven. - 009 top line, Not Yet Met Median OS of 6+ months for all dose cohorts, for patients who have a 2.5/3 mos. Stifel is engaged $abbv $rhhby or $bmy You can expect big pharma and or the 'market' to add a few hundred million to this $80m nano cap, just based on the true value of 009.